G2Gbio peptide reaches final preclinical stage as company targets global deal
AI Summary- G2Gbio advanced its Boehringer Ingelheim peptide compound to final preclinical evaluation.
- G2Gbio targets a global deal this year, chief executive Lee Hee-yong said.
- G2Gbio signed a July memorandum with Celltrion for antibody-delivery technology development.